Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection.

The screening of neo-angiogenesis related gene expression has uncovered many disrupted molecular pathways which may significantly confer to malignant transformation of various cell types including cervical cells. The objective of the present study was to delineate whether changes in certain gene expression profiles during the malignant conversion of the uterine cervix can be potentially used to predict the clinical course and outcome of the cervical pathology. Total RNA was isolated from Pap smears obtained from healthy females or patients diagnosed with low-grade squamous cervical intraepithelial lesions (LG-SIL), high-grade (HG)-SIL or cervical carcinoma. VEGF, TGF-beta1 and YY1 mRNA expression levels were assessed by QRT-PCR. Confirmation of YY1 protein discrepancy among cervical tissues of different histopathology was performed by immunohistochemistry. All tested genes showed statistically significant expression variations among the indicated groups. VEGF and TGF-beta1 mRNA overexpression was found to be associated with progression from low-grade to high-grade cervical intraepithelial neoplasia (CIN), while YY1 showed constitutively elevated transcript levels in CIN and cervical cancer compared to controls. At the protein level YY1 was also overexpressed in HG-SIL and cancer tissues compared to LG-SIL. Both YY1 transcript and protein overexpression were associated with HPV18- or HPV16-infected samples. Spearman analysis revealed a co-expression pattern for VEGF and TGF-beta1 mRNAs in normal cervix and LG-SIL; however, YY1 expression correlated negatively with VEGF and TGF-beta1 transcript levels upon the onset of the cervical neoplastic transformation. Our findings provide for the first time evidence for the implication of YY1 in uterine cervix carcinogenesis and suggest that VEGF, TGF-beta1 and YY1 could be useful biomarkers of cervical malignant transformation as well as potential targets for therapeutic approaches.

[1]  B. Bonavida,et al.  Transcription factor YY1: structure, function, and therapeutic implications in cancer biology , 2006, Oncogene.

[2]  S. Horvath,et al.  Expression of transcription factor Yin Yang 1 in prostate cancer. , 2005, International journal of oncology.

[3]  R. Kraft,et al.  Caspase-Dependent Regulation and Subcellular Redistribution of the Transcriptional Modulator YY1 during Apoptosis , 2005, Molecular and Cellular Biology.

[4]  D. Spandidos,et al.  VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. , 2005, Cancer letters.

[5]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[6]  C. Heldin,et al.  Nuclear Factor YY1 Inhibits Transforming Growth Factor β- and Bone Morphogenetic Protein-Induced Cell Differentiation , 2003, Molecular and Cellular Biology.

[7]  Kwangmoon Lee,et al.  Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix. , 2002, International journal of radiation oncology, biology, physics.

[8]  C. Heldin,et al.  Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. , 2002, Immunology letters.

[9]  L. Khachigian,et al.  Induction of the Transcriptional Repressor Yin Yang-1 by Vascular Cell Injury , 2001, The Journal of Biological Chemistry.

[10]  G. Fleuren,et al.  Cytokine profile of cervical cancer cells. , 2001, Gynecologic oncology.

[11]  T. Out,et al.  Cytokines in cervicovaginal washing fluid from patients with cervical neoplasia. , 2001, Cytokine.

[12]  P. Tighe,et al.  Decreased synthesis and expression of TGF‐β1, β2, and β3 in epithelium of HPV 16‐positive cervical precancer: a study by microdissection, quantitative RT‐PCR, and immunocytochemistry , 2000 .

[13]  Chien-Nan Lee,et al.  Vascular Endothelial Growth Factor and Prognosis of Cervical Carcinoma , 2000, Obstetrics and gynecology.

[14]  B. Weyn,et al.  The association between vascular endothelial growth factor, microvessel density and clinicopathological features in invasive cervical cancer. , 2000, European journal of obstetrics, gynecology, and reproductive biology.

[15]  H. Ngan,et al.  FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. , 2000, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[16]  H. Lodish,et al.  Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.

[17]  D. Spandidos,et al.  High prevalence of HPV18 in correlation with ras gene mutations and clinicopathological parameters in cervical cancer studied from stained cytological smears. , 1999, Oncology reports.

[18]  Yang Shi,et al.  Targeted Disruption of Mouse Yin Yang 1 Transcription Factor Results in Peri-Implantation Lethality , 1999, Molecular and Cellular Biology.

[19]  E. Seto,et al.  Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? , 1999, Gene.

[20]  H. Pfister,et al.  Overlapping YY1- and aberrant SP1-binding sites proximal to the early promoter of human papillomavirus type 16. , 1999, The Journal of general virology.

[21]  C. N. Lee,et al.  Vascular endothelial growth factor in cervical carcinoma. , 1999, Obstetrics and gynecology.

[22]  D. Sherer,et al.  Angiogenesis in malignancies of the female genital tract. , 1999, Gynecologic oncology.

[23]  M. Klinnert,et al.  Interleukin-10 and transforming growth factor-β promoter polymorphisms in allergies and asthma , 1998 .

[24]  D. Spandidos,et al.  Detection of HPV and ras gene mutations in cervical smears from female genital lesions. , 1998, Oncology reports.

[25]  P. Delvenne,et al.  Cytokine expression in squamous intraepithelial lesions of the uterine cervix: implications for the generation of local immunosuppression , 1998, Clinical and experimental immunology.

[26]  B. Rose,et al.  Point mutations in SP1 motifs in the upstream regulatory region of human papillomavirus type 18 isolates from cervical cancers increase promoter activity. , 1998, The Journal of general virology.

[27]  Anita B. Roberts,et al.  REGULATION OF IMMUNE RESPONSES BY TGF-β* , 1998 .

[28]  A. Kaider,et al.  Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia. , 1997, Journal of the National Cancer Institute.

[29]  Jeng-Shin Lee,et al.  Everything you have ever wanted to know about Yin Yang 1...... , 1997, Biochimica et biophysica acta.

[30]  G. Parham,et al.  Differential transforming growth factor-beta secretion in adenocarcinoma and squamous cell carcinoma of the uterine cervix. , 1997, Gynecologic oncology.

[31]  Bernhard Lüscher,et al.  Characterization of the Transcriptional Regulator YY1 , 1997, The Journal of Biological Chemistry.

[32]  K. Flanders,et al.  Altered expression of transforming growth factor‐β1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix , 1996, Cancer.

[33]  Anthony J. Guidi,et al.  Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. , 1995, Journal of the National Cancer Institute.

[34]  J. Flanagan.  Autologous stimulation of YY1 transcription factor expression: role of an insulin-like growth factor. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[35]  G. Trinchieri,et al.  IL-12 is expressed and released by human keratinocytes and epidermoid carcinoma cell lines. , 1994, Journal of immunology.

[36]  F. Stubenrauch,et al.  Prevalence of deletions of YY1‐binding sites in episomal HPV 16 DNA from cervical cancers , 1994, International journal of cancer.

[37]  F. Hoppe-Seyler,et al.  Cellular control of human papillomavirus oncogene transcription , 1994, Molecular carcinogenesis.

[38]  S. Wahl,et al.  Transforming growth factor β : a matter of life and death , 1994 .

[39]  K. Smith-McCune,et al.  Demonstration and characterization of the angiogenic properties of cervical dysplasia. , 1994, Cancer research.

[40]  K. Münger,et al.  The human papillomavirus E7 protein as a transforming and transactivating factor. , 1993, Biochimica et biophysica acta.

[41]  R. Schlegel,et al.  The viral transcriptional regulatory region upstream of the E6 and E7 genes is a major determinant of the differential immortalization activities of human papillomavirus types 16 and 18 , 1991, Journal of virology.

[42]  R. Schlegel,et al.  Differences in transformation activity between HPV-18 and HPV-16 map to the viral LCR-E6-E7 region. , 1991, Virology.

[43]  M. Sporn,et al.  Deactivation of macrophages by transforming growth factor-β , 1988, Nature.

[44]  A. Ammann,et al.  Suppression of immune cell function in vitro by recombinant human transforming growth factor-beta. , 1988, Cellular immunology.

[45]  D. Spandidos,et al.  Evaluation of the prevalence of human papillomavirus and Epstein-Barr virus in esophageal squamous cell carcinomas. , 2005, The International journal of biological markers.

[46]  L. Palmer,et al.  Transforming growth factor-beta1 promoter polymorphism C-509T is associated with asthma. , 2004, American journal of respiratory and critical care medicine.

[47]  A. Balmain,et al.  TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.

[48]  P. Tighe,et al.  Decreased synthesis and expression of TGF-beta1, beta2, and beta3 in epithelium of HPV 16-positive cervical precancer: a study by microdissection, quantitative RT-PCR, and immunocytochemistry. , 2000, The Journal of pathology.

[49]  T. Spector,et al.  Genetic control of the circulating concentration of transforming growth factor type beta1. , 1999, Human molecular genetics.

[50]  A. Roberts,et al.  Regulation of immune responses by TGF-beta. , 1998, Annual review of immunology.

[51]  S. Wahl,et al.  Transforming growth factor beta: a matter of life and death. , 1994, Journal of leukocyte biology.

[52]  M. Sporn,et al.  Deactivation of macrophages by transforming growth factor-beta. , 1988, Nature.